Correlation of HbA1c with Serum Lipid Profile in Patients with Type 2 Diabetes Mellitus in Mithilanchal Area
- 1. Assistant Professor, Department of Physiology, Shree Narayan Medical Institute & Hospital, Saharsa, Bihar
- 2. Assistant Professor, Department of Pathology, Shree Narayan Medical Institute & Hospital, Saharsa, Bihar
- 3. Professor and Head of Department, Department of Physiology, Darbhanga Medical College & Hospital, Laheriasarai, Bihar
Description
Background: Diabetes mellitus is a diverse set of diseases caused by a variety of etiologies, genetic and environmental factors operating in concert. These diseases are characterised by a state of persistent hyperglycemia. The gold-standard indicator of chronic glycaemia in diabetes individuals is glycated haemoglobin (HbA1c). The key indicator of mean blood glucose level is HbA1c. Dyslipidemia, particularly elevated LDL, is prevalent in diabetes mellitus and is closely linked to inadequate glycemic control. Objective: to determine the relationship between HbA1C and lipid profile in Mithilanchal area patients with Type 2 Diabetes Mellitus. Method: Present study was conducted at Department of Physiology, DMC, Laheriasarai, Bihar. A total of 60 confirmed cases of type 2 diabetes mellitus were obtained from DMCH, Medicine Department. Males and females were included in the samples (40 -60 YR). As a control, 60 people of a similar age range without diabetes were used. Between the case and control groups, the following parameters were examined and compared: FBS, PPBS, HbA1c, TG, Chol., HDL, LDL, and VLDL. Result: The case group had significantly higher FBS, PPBS, and HbA1C levels. HDL is much lower than the control group, but LDL, CHOL, and TG were high in this case. Patients’ values for HbA1C/LDL, HbA1C/HDL, and HbA1C/CHOL are statistically strongly significant when compared to controls. Significant correlation exists between lipid profiles and HbA1c. Conclusion: Patients with type 2 diabetes are more likely to develop dyslipidaemia. Significant correlation exists between lipid profiles and HbA1c. Therefore, in addition to serving as a biomarker for glycemic control in type 2 diabetes, HbA1c can also be employed as an indirect predictor of dyslipidaemia.
Abstract (English)
Background: Diabetes mellitus is a diverse set of diseases caused by a variety of etiologies, genetic and environmental factors operating in concert. These diseases are characterised by a state of persistent hyperglycemia. The gold-standard indicator of chronic glycaemia in diabetes individuals is glycated haemoglobin (HbA1c). The key indicator of mean blood glucose level is HbA1c. Dyslipidemia, particularly elevated LDL, is prevalent in diabetes mellitus and is closely linked to inadequate glycemic control. Objective: to determine the relationship between HbA1C and lipid profile in Mithilanchal area patients with Type 2 Diabetes Mellitus. Method: Present study was conducted at Department of Physiology, DMC, Laheriasarai, Bihar. A total of 60 confirmed cases of type 2 diabetes mellitus were obtained from DMCH, Medicine Department. Males and females were included in the samples (40 -60 YR). As a control, 60 people of a similar age range without diabetes were used. Between the case and control groups, the following parameters were examined and compared: FBS, PPBS, HbA1c, TG, Chol., HDL, LDL, and VLDL. Result: The case group had significantly higher FBS, PPBS, and HbA1C levels. HDL is much lower than the control group, but LDL, CHOL, and TG were high in this case. Patients’ values for HbA1C/LDL, HbA1C/HDL, and HbA1C/CHOL are statistically strongly significant when compared to controls. Significant correlation exists between lipid profiles and HbA1c. Conclusion: Patients with type 2 diabetes are more likely to develop dyslipidaemia. Significant correlation exists between lipid profiles and HbA1c. Therefore, in addition to serving as a biomarker for glycemic control in type 2 diabetes, HbA1c can also be employed as an indirect predictor of dyslipidaemia.
Files
IJPCR,Vol14,Issue12,Article58.pdf
Files
(274.0 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:de1ffc8c75cab98bde176975c0f83db9
|
274.0 kB | Preview Download |
Additional details
Dates
- Accepted
-
2022-12-09
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/14/IJPCR,Vol14,Issue12,Article58.pdf
- Development Status
- Active
References
- 1. Lt Gen SR Mehta, VSM, Col AS Kashyap, Lt Col S Das. Diabetes Mellitus in India: The Modern Scourge. MJAFI 2009; 65:50-4. 2. Surekha Rani. H, Madhavi G, Ramachandra Rao V, Sahay B.K, Jyothy A. Risk Factors for Coronary Heart Disease in Type II DM. Indian Journal of Clinical Biochemistry 2005;20(2):75-80. 3. Zachary T, Bloomgarden. Cardiovascular Disease, Neuropathy and Retinopathy. Diabetes care 2009;32: e64- e 68. 4. Chambless LE, Heiss G, Folsom AR, Rosamond W,Szklo M, Sharrett AR, Clegg LX. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Mahantesh Patilet. al. Int J Cur Res Rev, March 2014/ Vol 06 (06) Page 24 Risk in Communities (ARIC) Study, 1987– 1993. Am J Epidemiol 1997; 146:483–94. 5. Burtis Carl A, Ashwood Edward R, Bruns David E.Tietz Textbook of clinical chemistry and molecular diagnostics. 4th Ed. New dehli: Elsevier publishers; 2008. Chapter 26, Lipids, lipopropteins, apolipoproteins and other cardiovascular risk factors: 2008; 903-83. 6. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2000;23(Suppl 1): S32–42. 10. 7. Rath M, Ncendorf A, Reblin T, Dietel M, Knebber HJ. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Atherosclerosis 1989; 9:579-92. 8. KhareKC, Raman PG, Bhatnagar AD, ReemaBhavsar. Serum Lp(a) levels in patients of diabetes mellitus. Int. J. Diab. Dev. Countries 2000; 20:79 – 83.9. Robert McCarter J, James Hempe M, Ricardo Gomez, Stuart Chalew A. Biological Variation in HbA1c Predicts Risk of Retinopathy and Nephropathy in Type 1 Diabetes. Diabetes Care 2004; 27:1259–64. 10. Surekha Rani. H, Madhavi G, Ramachandra Rao V, Sahay B.K, Jyothy A. Risk Factors for Coronary Heart Disease in Type II DM. Indian Journal of Clinical Biochemistry 2005;20(2):75-80. 11. Elizabeth Selvin, Josef Coresh, Sherita Golden H, Lori L. Boland, Frederick Brancati L, Michael Steffes W. Glycemic Control, Atherosclerosis, and Risk Factors for Cardiovascular Disease in Individuals with Diabetes. Diabetes Care. 2005;28(8):1965–73. 12. Mahantesh Patil, Nirmal Kumar, Aliya Nusrath, Shubha Jayaram, Rajeshwari A. Association of HbA1c with serum lipid profile and lipoprotein (a) In type 2 Diabetes Mellitus. Int J Cur Res Rev. 2014; 06(06): 20-25. 13. Boden G; Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes, 1997; 46(1):4755. 14. Mgonda YM, Ramaiya KL, Swai AB, McLarty DG, Alberti KG. Insulin resistance and hypertension in non-obese Africans in Tanzania. Hypertension. 1998; 31(1):114-118. 15. Carmena R. High risk of lipoprotein dysfunction in type 2 diabetes mellitus. Rev Esp Cardiol Supl., 2008; 8 (supl C): 18C-24C. 16. Wexler, D.J., Grant, R.W., Meigs, J.B., Nathan, D.M and Cagliero, E. Sex disparities in the treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care, 2005; 28:514-520. 17. Rosmee and Shyamal Koley. Association of HbA1c with Lipid profiles in patients with type 2 diabetes mellitus. International Journal of Biomedical Research 2016; 7(3): 139-143. 18. Erciyas F., Taneli F., Arslan B., and Uslu, Y. Glycemic control, oxidative stress and lipid profile in children with type 1 Diabetes Mellitus. Arch. Med. Res. 2004; 35:134-140. 19. Rohlfling C.L., Wiedmeyer H.M., Little R.R., England J.D., Tennill A. and Goldstein D.E. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in Diabetes Control and Com-plications trial. Diabetes Care 2002; 25: 275-278. 20. Khaw K.T., Wareham N., Luben R., Bingham S., Okas S., Welch A., Glycated hemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPICNorfolk). Br. Med. J. 2001; 322:15-18.